H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Argenx (ARGX) with a $617 price target after the company said it is advancing efgartigimod subcutaneous in all three subtypes of ...
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for ...
Cartesian Therapeutics (RNAC) is maintained at a "Buy" rating, driven by progress in its Descartes-08 mRNA CAR-T pipeline for autoimmune disorders. RNAC's phase 3 AURORA study targets AChR Ab+ ...
PHILADELPHIA, May 16, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies ...
Argenx Se (ARGX) has released an update. Don't Miss our Black Friday Offers: Argenx SE is advancing the clinical development of its subcutaneous treatment, efgartigimod SC, for idiopathic inflammatory ...
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback